| NEDD9 promotes oncogenic signaling in mammary tumor development E Izumchenko, MK Singh, OV Plotnikova, N Tikhmyanova, JL Little, ... Cancer research 69 (18), 7198-7206, 2009 | 152 | 2009 |
| Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle MK Singh, L Cowell, S Seo, GM O’Neill, EA Golemis Cell biochemistry and biophysics 48 (1), 54-72, 2007 | 141 | 2007 |
| A novel Cas family member, HEPL, regulates FAK and cell spreading MK Singh, D Dadke, E Nicolas, IG Serebriiskii, S Apostolou, A Canutescu, ... Molecular biology of the cell 19 (4), 1627-1636, 2008 | 96 | 2008 |
| Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle D Dadke, M Jarnik, EN Pugacheva, MK Singh, EA Golemis Molecular biology of the cell 17 (3), 1204-1217, 2006 | 69 | 2006 |
| Mutational spectrum of K‐ras oncogene among Indian patients with gallbladder cancer MK Singh, K Chetri, UB Pandey, VK Kapoor, B Mittal, G Choudhuri Journal of gastroenterology and hepatology 19 (8), 916-921, 2004 | 56 | 2004 |
| Apolipoprotein B-100 XbaI gene polymorphism in gallbladder cancer MK Singh, UB Pandey, UC Ghoshal, I Srivenu, VK Kapoor, G Choudhuri, ... Human genetics 114 (3), 280-283, 2004 | 46 | 2004 |
| Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9 MK Singh, E Izumchenko, AJ Klein-Szanto, BL Egleston, M Wolfson, ... Cancer research 70 (21), 8907-8916, 2010 | 41 | 2010 |
| HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins MK Singh, E Nicolas, W Gherraby, D Dadke, S Lessin, EA Golemis Oncogene 26 (33), 4825, 2007 | 38 | 2007 |
| Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers R Mehra, F Zhu, DH Yang, KQ Cai, JE Weaver, MK Singh, AS Nikonova, ... Clinical Cancer Research 19 (23), 6633-6643, 2013 | 32 | 2013 |
| Total PSA and free PSA in patients with severe liver dysfunction RD Mittal, MK Singh, C Selvaraju, G Choudhuri Indian Journal of Urology 19 (2), 117, 2003 | 8 | 2003 |
| Gallbladder Cancer and Aflatoxin: Do We Have Sufficient Evidence? MK Singh, VK Kapoor Gastroenterology 154 (1), 259-260, 2018 | 2 | 2018 |
| Internet resources for the human geneticist. SK Pal, MK Singh, GS Pandey, B Mittal | 2 | 2001 |
| Evaluation of Minnelide as potential targeted therapy for triple negative breast cancer MK Singh, S Shah, NS Sharma, B Giri, S Banerjee, A Saluja Cancer Research 77 (13 Supplement), 5119-5119, 2017 | 1 | 2017 |
| Re: Dutta et al.—gallbladder cancer MK Singh, G Choudhuri The American journal of gastroenterology 98 (4), 936, 2003 | 1* | 2003 |
| Non surgical palliation of malignant obstructive jaundice in northern India: problems posed by gallbladder cancer (GBC) G Choudhuri, MK Singh, K Chetri, A Kumar, L Peter, S Mohindra, TS Negi, ... The American Journal of Gastroenterology 95 (9), 2474, 2000 | 1 | 2000 |
| Gastroenterology and the Internet. MK Singh, SK Pal, VK Kapoor, G Choudhuri Tropical gastroenterology: official journal of the Digestive Diseases …, 2000 | 1 | 2000 |
| Triptolide pro-drug decreases tumor burden and halts tumor progression in a murine model of acute myeloid leukemia B Giri, S Banerjee, J George, S Modi, VK Gupta, MK Singh, V Dudeja, ... Cancer Research 76 (14 Supplement), 3499-3499, 2016 | | 2016 |
| NEDD9 is required for initiation of HER2/Neu-dependent mammary tumor development JL Little, E Izumchenko, MK Singh, S Seo, M Kurokawa, BL Egleston, ... Cancer Research 70 (8 Supplement), 3257-3257, 2010 | | 2010 |
| Abstract B106: Nedd9 null status initially delays mammary tumor growth, then selects for hyper‐aggressive mammary tumors MK Singh, E Izumchenko, AJP Klein‐Szanto, EA Golemis Molecular Cancer Therapeutics 8 (12 Supplement), B106-B106, 2009 | | 2009 |
| Abstract# 2087: HEF1/NEDD9/CasL is required for activation of oncogenic signaling pathways in mammary tumor development E Izumchenko, O Plotnikova, M Singh, N Tikhmyanova, J Little, S Seo, ... Cancer Research 69 (9 Supplement), 2087-2087, 2009 | | 2009 |
Erica GolemisProfessor, Assoc. Director for System Integration, Fox Chase Cancer Center, and Chair, LKSOMVerifisert e-postadresse på fccc.edu
